메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states

Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.
- 김갑성 기자
- 2025-08-27 20:00
Innovent Announces 2025 Interim Results and Business Updates

[ 메디채널 김갑성 기자 ] Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu, Found
- 김갑성 기자
- 2025-08-27 18:08
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum

CHENGDU, China, Aug. 27, 2025 -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core product, Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®. The drug generated net sales of approximately RMB 170 million. Keymed strengthened its balance sheet with a successful placement raising ~HK$864 million, providing ample funds for pipeline development and commercialization.
- 김갑성 기자
- 2025-08-27 14:02
Digital twin technology with AI to boost efficiency and reliability in pharmaceutical manufacturing

Cambridge Advanced Research and Education in Singapore (CARES), the University of Cambridge's first overseas research centre, together with the A*STAR Institute for Infocomm Research (A*STAR I2R) has developed a digital twin platform that uses artificial intelligence (AI) and real-time plant data to enhance fault detection, system monitoring, and predictive maintenance in pharmaceutical manufacturing. The technology will be commercialised through Chemical Data Intelligence, a CARES spin-off, and will be made available to the Pharma Innovation Programme Singapore (PIPS) Consortium.
- 김갑성 기자
- 2025-08-27 13:00
Crescom to Showcase Musculoskeletal AI Innovations at 26th Asian Musculoskeletal Society Annual Meeting

[ 메디채널 김갑성 기자 ] Company to present MediAI solution suite and strengthen partnerships for expansion across Southeast and East Asia SEOUL, South Korea, Aug. 27, 2025 -- Crescom, a leader in AI-powered musculoskeletal (MSK) image analysis software, announced its participation in the 26th Asian Musculoskeletal Society (AMS) Annual Meeting which takes place from August 29 through 31 at Singapore EXPO. At the event, Crescom will host an exhibition booth to showcase its AI solution suite and engage directly with healthcare professionals across the region. The company aims to
- 김갑성 기자
- 2025-08-27 09:00
TheChallenge.org: New Study by Finds Reducing Phone Use is Over Twice as Hard as Enduring a Daily Ice Bath

WARSAW, Poland, Aug. 27, 2025 -- A new social study involving 9,150 participants from 47 countries has revealed a startling modern truth: most people find it significantly harder to reduce their screen time than to plunge into a barrel of ice water every day. The study, conducted by the health and wellness project TheChallenge.org, centered on its 31-Day "Digital Detox Challenge." Participants committed to simple rules like two screen-free hours daily and a 30-minute social media cap. Despite the profound benefits reported by those who completed it, the challenge had
- 김갑성 기자
- 2025-08-27 03:37
세레신, 영국 국립보건의료연구원(NIHR) 뇌 건강 헬스테크 연구센터(HRC) 산업 파트너로 합류

덴버, 2025년 8월 27일 -- 신경대사 분야를 선도하는 글로벌 바이오텍 기업 세레신이 영국의 국립보건의료연구원(NIHR) 뇌 건강 헬스테크 연구센터 (HRC)와 파트너십을 체결했습니다. 이번 협력으로 세레신은 GE 헬스케어, 노보 노디스크, 로슈 다이애그노스틱스, 그리고 윌마 인터내셔널 산하의 캄텍 이노베이션 등 업계를 선도하는 세계적인 기업들과 함께 HRC의 일원이 되었습니다. 영국 킹스칼리지 런던(King's College London)과 사우스 런던 앤 모즐리 NHS 재단 (South London and Maudsley NHS Foundation Trust)에 기반을 둔 NIHR 헬스테크 연구센터(HRC)는 선진 기술을 바탕으로 활용하여 치매 진단, 돌봄 및 치료의 발전에 집중하는 연구기관입니다. 본 센터는 뇌 스캔, 혈액 채취, 컴퓨터를 이용한 검사 및 디지털 도구를 활용하여 치매를 보다 효과적이고 조기에 진단하는 방법을 개발할 예정이며, 이를 통해 치매가 사회 전반에 미치는 영향을 완화하는 것을 목표로 합니다. HRC는 킹스칼리지 런던 산하 정신의학, 심리학 및 신경과학 연구소
- 김갑성 기자
- 2025-08-27 00:13
Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner

DENVER, Aug. 27, 2025 -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations. The HRC, based at King's College London and the South London and Maudsley NHS Foundation Trust, is dedicated to advancing the diagnosis, care, and treatment of dementia through cutting-edge technologies. The Centre will leverage brain scanning, bloo
- 김갑성 기자
- 2025-08-27 00:04
MagMutual Transforms Operations with Appian

Appian AI-powered platform cuts policy migration time, accelerates quoting, and unifies operations. MCLEAN, Va., Aug. 26, 2025 -- Appian (NASDAQ: APPN) today announced that MagMutual has successfully transformed its operations using Appian's AI-powered platform. MagMutual is a leading provider of medical malpractice insurance, delivering comprehensive coverage to more than 40,000 healthcare providers and organizations across the United States. It partnered with Appian and Xebia to modernize its core processes and elevate the policyholder experience. The insurer faced mou
- 황정호 기자
- 2025-08-26 21:00
iNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing Technology

[ 메디채널 김갑성 기자 ] Development of gene-editing technology for Pasteurella bacteriophages using the IMPA™ platform Establishment of an advanced platform technology based on CRISPR-Cas9 and recombination for Pasteurella Patent applications filed for core proprietary technology enabling the incorporation of diverse payloads BOSTON and SEOUL, South Korea, Aug. 26, 2025 -- iNtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a new IMPA™ gene
- 김갑성 기자
- 2025-08-26 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-04_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 12시 20분